Use of Water Ingestion in Small Intestine Ultrasound
Observational · No treatment assigned · 1 site · Austin Health
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Crohn Disease (CD) and Intestine Ultrasonography. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 to 80
- Any sex
Some of the main requirements, copied from the record:
- All consecutive patients at baseline scan with:
- Confirmed or suspected Crohn's disease with small bowel involvement
- Increased bowel wall thickness (>3mm) of the terminal ileum
Plus 2 more requirement(s). There are also 3 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 55 participants are expected to take part.
- Start date: 2025-07 (planned).
- Main results expected around 2025-11 (estimate from the record).
- 1 study site listed in Australia.
Main thing being measured
- Improvement of luminal distension of the terminal ileum (At the post-water ingestion scan 20-30 minutes after ingestion)
In the researchers’ words
Small Intestine Contrast Ultrasonography (SICUS) is an ultrasound-based method that explores bowel loops, and is able to identify wall thickness, intestinal motility, bowel wall vascularity and complications such as stenosis or dilatation. Previous studies have utilised oral ingestion of an oral contrast solution (usually PEG dissolved in a volume of water ranging from 250 to 1000mL), in order to increase the…
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Crohn Disease (CD); Intestine Ultrasonography |
| Lead sponsor | Austin Health |
| Enrollment | 55 (estimated) |
| Start date | 2025-07 |
| Primary completion (est.) | 2025-11 |
| First posted | 2025-07-22 |
| Last updated | 2025-07-22 |
| Official title | Use of Water Ingestion to Improve Visualisation in Small Intestine Ultrasound (WIVIUS): Single Centre Blinded Crossover Trial |
| ClinicalTrials.gov ID | NCT07079007 |
Interventions
- Water (Other)
Patients that meet the inclusion and exclusion criteria would be asked to ingest 1000ml water as part of standard of care.
Full eligibility criteria (from the record)
Inclusion Criteria: All consecutive patients at baseline scan with: * Confirmed or suspected Crohn's disease with small bowel involvement * Increased bowel wall thickness (>3mm) of the terminal ileum * Suboptimal luminal distension of the terminal ileum 3cm proximal to ICV and 1cm proximal to diseased segment (defined as <8mm) * All patients with an ileo-colic anastomosis Exclusion Criteria: * Presence of an ostomy * Adequate distension at baseline scan * Patients with ileo-rectal anastomosis or IPAA
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Austin Health | Heidelberg, Victoria | Australia |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.